| Typhoid Polysaccaride Vaccine |
1354/28.12.2007 |
TYPHERIX, Solution for injection, 0,5 ml/1 dose, -, Pack: 1 pre-filled syrigne + 2 needels |
ГлаксоСмитКлайн ЕООД, България |
GlaxoSmithKline Biologicals, Belgium |
13.69 |
2.74 |
16.43 |
6% |
0.82 |
14.51 |
2.9 |
17.41 |
18% |
2.46 |
16.97 |
3.39 |
20.36 |
|
КЦ-1238/18.12.2009 |
06.01.2010 |
06.01.2010 |
Активен |
844 |
| Typhoid Polysaccaride Vaccine |
II-0654/21.09.2007 |
Typhim Vi, Solution for injection, 0,5 ml/1 dose, -, Pack: 1pre-filled syringe |
Sanofi Pasteur S.A., Франция |
Sanofi Pasteur S.A., France; Sanofi-Aventis, Унгария |
16.55 |
3.31 |
19.86 |
6% |
0.99 |
17.54 |
3.51 |
21.05 |
18% |
2.98 |
20.52 |
4.1 |
24.62 |
промяна на обстоятелства НСР-5489/23.01.2015 |
КЦ-723/16.03.2009 |
03.04.2009 |
03.04.2009 |
Активен |
668 |
| Bisoprolol |
20120281/04.06.2012 |
Tyrez, Film coated tablet, 5, mg, Pack: 30 |
Alkaloid – INT d.o.o., Словения |
Alkaloid – INT d.o.o., Šlandrova ulica 4, 1231 Ljubljana, Črnuče, Словения |
1.9 |
0.38 |
2.28 |
7% |
0.13 |
2.03 |
0.41 |
2.44 |
20% |
0.38 |
2.41 |
0.48 |
2.89 |
цената се заличава HCР-449/09.07.2013 |
КЦРР-1729/04.12.2012 г |
20.12.2012 |
20.12.2012 |
Заличен |
1475 |
| Bisoprolol |
20120282/04.06.2012 |
Tyrez, Film coated tablet, 10, mg, Pack: 30 |
Alkaloid – INT d.o.o., Словения |
Alkaloid – INT d.o.o., Šlandrova ulica 4, 1231 Ljubljana, Črnuče, Словения |
3.13 |
0.63 |
3.76 |
7% |
0.22 |
3.35 |
0.67 |
4.02 |
20% |
0.63 |
3.98 |
0.8 |
4.78 |
цената се заличава HCР-450/09.07.2013 |
КЦРР-1729/04.12.2012 г |
20.12.2012 |
20.12.2012 |
Заличен |
1476 |
| Bisoprolol |
20120280/04.06.2012 |
Tyrez, Film coated tablet, 2.5, mg, Pack: 30 |
Alkaloid – INT d.o.o., Словения |
Alkaloid – INT d.o.o., Šlandrova ulica 4, 1231 Ljubljana, Črnuče, Словения |
1.7 |
0.34 |
2.04 |
7% |
0.12 |
1.82 |
0.36 |
2.18 |
20% |
0.34 |
2.16 |
0.43 |
2.59 |
цената се заличава HCР-448/09.07.2013 |
КЦРР-1729/04.12.2012 г |
20.12.2012 |
20.12.2012 |
Заличен |
1474 |
| Natalizumab |
ЕU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, -, Pack: 1 vial |
Biogen Idec Limited, Обединено Кралство |
Biogen Denmark Manufacturing ApS, Дания |
2416.76 |
483.35 |
2900.11 |
4% |
10 |
2426.76 |
485.35 |
2912.11 |
16% |
25 |
2451.76 |
490.35 |
2942.11 |
промяна на обстоятелства НСР-9437/01.06.2016 |
НСР-4940/22.10.2014; НСР-9972/29.07.2016 |
02.09.2016 |
02.09.2016 |
Активен |
3295 |
| Natalizumab |
ЕU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Biogen Idec Limited, Обединено Кралство |
Biogen Denmark Manufacturing ApS, Дания |
2465.83 |
493.17 |
2959 |
4% |
10 |
2475.83 |
495.17 |
2971 |
16% |
25 |
2500.83 |
500.17 |
3001 |
промяна на обстоятелства НСР-9437/01.06.2016 |
НСР-4940/22.10.2014 |
06.11.2014 |
06.11.2014 |
Неактивен |
3295 |
| Natalizumab |
ЕU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Elan Pharma International, Ирландия |
Biogen Idec Denmark Manufacturing ApS; Biogen Idec Alle 1 DK-3400 Hillerod, Denmark |
2465.83 |
493.17 |
2959 |
4% |
10 |
2475.83 |
495.17 |
2971 |
16% |
25 |
2500.83 |
500.17 |
3001 |
|
НСР-4940/22.10.2014 |
06.11.2014 |
06.11.2014 |
Неактивен |
3295 |
| Natalizumab |
ЕU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Elan Pharma International, Ирландия |
Biogen Idec Denmark Manufacturing ApS; Biogen Idec Alle 1 DK-3400 Hillerod, Denmark |
2556.45 |
511.29 |
3067.74 |
4% |
10 |
2566.45 |
513.29 |
3079.74 |
16% |
25 |
2591.45 |
518.29 |
3109.74 |
|
НСР-2748/17.02.2014 |
06.03.2014 |
06.03.2014 |
Неактивен |
3295 |
| Natalizumab |
ЕU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Elan Pharma International, Ирландия |
Biogen Idec Denmark Manufacturing ApS; Biogen Idec Alle 1 DK-3400 Hillerod, Denmark |
2598.14 |
519.63 |
3117.77 |
4% |
10 |
2608.14 |
521.63 |
3129.77 |
16% |
25 |
2633.14 |
526.63 |
3159.77 |
|
HCР-21/31.05.2013 |
02.06.2013 |
02.06.2013 |
Неактивен |
3295 |
| Natalizumab |
EU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Elan Pharma International, Ирландия |
Biogen Idec Denmark Manufacturing ApS Biogen Idec Allé 1 DK-3400 Hillerød, Дания |
2832.12 |
566.42 |
3398.54 |
4% |
10 |
2842.12 |
568.42 |
3410.54 |
16% |
25 |
2867.12 |
573.42 |
3440.54 |
|
КЦРР-1059/26.07.2012 |
10.08.2012 |
10.08.2012 |
Неактивен |
3295 |
| Natalizumab |
EU/1/06/346/001 |
TYSABRI, Concentrate for solution for infusion, 300 mg (20 mg/ml)-15 ml, mg, Pack: 1 vial |
Elan Pharma International, Ирландия |
Biogen Idec Denmark Manufacturing ApS / Biogen Idec Allé 1 / DK-3400 Hillerød, Дания |
2979.49 |
595.9 |
3575.39 |
6% |
15 |
2994.49 |
598.9 |
3593.39 |
18% |
30 |
3024.49 |
604.9 |
3629.39 |
|
КЦ-648/05.03.2009 |
19.03.2009 |
19.03.2009 |
Неактивен |
3295 |
| Lapatinib |
EU/1/07/440/002 |
Tyverb, Film coated tablet, 250, mg, Pack: 140 |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Operations UK Ltd, UK |
4283.72 |
856.74 |
5140.46 |
6% |
15 |
4298.72 |
859.74 |
5158.46 |
18% |
30 |
4328.72 |
865.74 |
5194.46 |
Цената е заличена с решение КЦРР-932/04.07.2012 |
КЦ-328/28.11.2008 |
22.12.2008 |
22.12.2008 |
Заличен |
314 |
| Lapatinib |
EU/1/07/440/006 |
TYVERB, Film coated tablet, 250, mg, Pack: 84 |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd., UK |
2380.56 |
476.11 |
2856.67 |
4% |
10 |
2390.56 |
478.11 |
2868.67 |
16% |
25 |
2415.56 |
483.11 |
2898.67 |
Промяна на обстоятелства НСР- 6990/24.08.2015; корекционно решение НСР7539/19.11.2015 |
КЦ-2824/04.10.2011 |
18.10.2011 |
18.10.2011 |
Активен |
1113 |
| Lapatinib |
EU/1/07/440/005 |
TYVERB, Film coated tablet, 250, mg, Pack: 140 |
Novartis Europharm Limited, Обединено Кралство |
Glaxo Operations UK Ltd., UK; Glaxo Wellcome S.A., Spain |
3550.36 |
710.07 |
4260.43 |
4% |
10 |
3560.36 |
712.07 |
4272.43 |
16% |
25 |
3585.36 |
717.07 |
4302.43 |
Промяна на обстоятелства НСР- 6733/16.07.2015; Протокол 130/06.8.2015; корекционно решение НСР7538/19.11.2015 |
НСР-5131/27.11.2014 |
12.12.2014 |
12.12.2014 |
Активен |
3392 |
| Lapatinib |
EU/1/07/440/005 |
TYVERB, Film coated tablet, 250, mg, Pack: 140 |
Glaxo Group Ltd., Обединено Кралство |
Glaxo Operations UK Ltd., UK; Glaxo Wellcome S.A., Spain |
3967.6 |
793.52 |
4761.12 |
4% |
10 |
3977.6 |
795.52 |
4773.12 |
16% |
25 |
4002.6 |
800.52 |
4803.12 |
промяна в обстоятелства НСР-5132/27.11.2014 |
КЦ-2824/04.10.2011 |
18.10.2011 |
18.10.2011 |
Неактивен |
3392 |
| Omeprazole |
II-13748/07.07.2006 |
Ulcoprol, Powder for solution for infusion, 40, mg, Pack: 5 |
Актавис EАД, България |
Балканфарма - Разград АД, България; Sofarimex-Ind. Quimica e Farmaceutica, Lda - Portugal |
33.78 |
6.76 |
40.54 |
4% |
1.35 |
35.13 |
7.03 |
42.16 |
16% |
5.4 |
40.53 |
8.11 |
48.64 |
|
КЦ-507/06.02.2009 |
19.02.2009 |
19.02.2009 |
Активен |
492 |
| Omeprazole |
16197/06,04,2007 |
Ulcoprol, Gastro resistant capsule, hard, 20, mg, Pack: 30 |
Актавис EАД, България |
Балканфарма- Дупница АД |
6.88 |
1.38 |
8.26 |
7% |
0.48 |
7.36 |
1.47 |
8.83 |
20% |
1.38 |
8.74 |
1.75 |
10.49 |
Цената се вписва в регистъра на пределните цени с решение НСР-2153/14.12.2013 |
КЦ-279/14.11.2008 |
11.12.2008 |
11.12.2008 |
Заличен |
245 |
| Indacaterol and glycopyrronium bromide |
EU/1/13/862/003 |
Ultibro Breezhaler, Inhalation powder, hard capsule, 85 mcg /43 mcg, -, Pack: 30 x 1 capsules (unit dose) + 1 inhaler |
Novartis Europharm Limited, Обединено Кралство |
Novartis Pharma GmbH, Германия |
89.77 |
17.95 |
107.72 |
4% |
3.59 |
93.36 |
18.67 |
112.03 |
16% |
14.36 |
107.72 |
21.54 |
129.26 |
корекц. НСР-6456/18.06.2015 |
НСР-6138/29.04.2015. |
14.05.2015 |
14.05.2015 |
Активен |
3857 |
| Indacaterol and glycopyrronium bromide |
EU/1/13/862 |
Ultibro Breezhaler, Inhalation powder, hard capsule, 85 mcg/ 43 mcg, UD, Pack: 30 |
Novartis Europharm Limited, Обединено Кралство |
Novartis Pharma GmbH, Германия |
96.15 |
19.23 |
115.38 |
4% |
3.85 |
100 |
20 |
120 |
16% |
15.38 |
115.38 |
23.08 |
138.46 |
|
НСР-4636/15.09.2014 |
30.09.2014 |
30.09.2014 |
Неактивен |
3857 |
| Iopromide |
15104/06,12,2006 |
Ultravist, Solution for injection/infusion, 370mg/ml-500 ml, mg, Pack: 8 |
Bayer Pharma AG, Германия |
Bayer Pharma AG, Germany |
2735.4 |
547.08 |
3282.48 |
4% |
10 |
2745.4 |
549.08 |
3294.48 |
16% |
25 |
2770.4 |
554.08 |
3324.48 |
промяна на обстоятелства решение НСР-1159/13.09.2013 цената е вписана в регистъра на пределните цени с решение НСР-1159/13.09.2013 |
НСР-132/07.06.2013 |
08.07.2013 |
08.07.2013 |
Заличен |
1884 |
| Iopromide |
15104/06,12,2006 |
Ultravist, Solution for injection/infusion, 370mg/ml-500 ml, mg, Pack: 8 |
Schering AG, Германия |
Schering AG, Germany |
3775.73 |
755.15 |
4530.88 |
4% |
10 |
3785.73 |
757.15 |
4542.88 |
16% |
25 |
3810.73 |
762.15 |
4572.88 |
|
КЦ-353/19.12.2008 |
22.01.2009 |
22.01.2009 |
Неактивен |
1884 |
| Iopromide |
15104/06,12,2006 |
Ultravist, Solution for injection/infusion, 370mg/ml-100 ml, mg, Pack: 10 |
Bayer Pharma AG, Германия |
Bayer Pharma AG, Germany; BerliMed S.A., Spain |
538.07 |
107.61 |
645.68 |
4% |
10 |
548.07 |
109.61 |
657.68 |
16% |
25 |
573.07 |
114.61 |
687.68 |
|
НСР-6179/08.05.2015 |
25.05.2015 |
25.05.2015 |
Активен |
3928 |
| Iopromide |
20010204 |
Ultravist, Solution for injection/infusion, 370mg/ml-50 ml, mg, Pack: 10 |
Bayer Pharma AG, Германия |
Bayer Pharma AG, Germany; BerliMed S.A., Spain |
323.1 |
64.62 |
387.72 |
4% |
10 |
333.1 |
66.62 |
399.72 |
16% |
25 |
358.1 |
71.62 |
429.72 |
промяна на обстоятелства НСР-3339/24.04.2014; НСР-5020/17.11.2014 |
НСР-3042/21.03.2014 |
09.04.2014 |
09.04.2014 |
Активен |
2622 |
| Iopromide |
15104/06,12,2006 |
Ultravist, Solution for injection/infusion, 370mg/ml-100 ml, mg, Pack: 10 |
Bayer Pharma AG, Германия |
Bayer Pharma AG, Germany; BerliMed S.A., Spain |
654.32 |
130.86 |
785.18 |
4% |
10 |
664.32 |
132.86 |
797.18 |
16% |
25 |
689.32 |
137.86 |
827.18 |
промяна на обстоятелства НСР-3087/21.03.2014 |
НСР-3011/12.03.2014 |
28.03.2014 |
28.03.2014 |
Неактивен |
3928 |